Oncolytics Biotech (ONCY) announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company’s portfolio. Most recently, Mr. McAdory served as Vice President, Clinical Operations at CG Oncology (CGON). Most recently, Wu served as Head of Biostatistics at Morphic Therapeutic.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Advancing Pelareorep: Compelling Early Efficacy and High-Risk, High-Reward Valuation Support Buy Rating and $3 Target
- Oncolytics Biotech Data Signal Registration Path for Pelareorep Combo in Third-Line Anal Cancer
- Oncolytics announces updates data from GOBLET cohort 4
- Oncolytics Biotech Seeks Nevada Domestication to Align with U.S. Growth Strategy
- Oncolytics outlines strategic rationale for proposal to change jurisdiction